Article

Adjuvant IL-2 offers survival benefit in metastatic RCC

Author(s):

Orlando, FL-In patients with metastatic renal cell carcinoma, adjuvant interleukin-2 (IL-2) after cytoreductive nephrectomy appears to offer a superior survival benefit over nephrectomy followed by interferon alpha-2b, according to a report presented here at the American Society of Clinical Oncology annual meeting.

Related Videos
Yahir A. Santiago-Lastra, MD, answers a question during a Zoom video interview
1 expert is featured in this series.
1 expert is featured in this series.
Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
2 experts are featured in this series.
2 experts are featured in this series.
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
© 2025 MJH Life Sciences

All rights reserved.